Oxurion (OXUR.BR) Stock Price

Oxurion Price

Euronext Brussels·CLOSED
0.00
​
Market closed

Revenue at Oxurion has contracted by 33.0% per year over the past 19 years to 3,000.00 EUR. Earnings per share have declined at 14.4% per year over the last 16 years. Oxurion's net margin stands at 3,966.7%, up from -1,348.0% several years earlier.

Oxurion stock price

Access this data via the Eulerpool API

Oxurion business model & stock analysis

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 77 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.

Frequently asked questions about Oxurion

9 analysts currently rate the Oxurion stock: 0 recommend buying, 3 holding and 6 selling.

The Oxurion share (OXUR.BR) is listed on 7 stock exchanges, including: London (0G99.L), SIX (Zürich) (THR.SW), Frankfurt (TG4.F), Düsseldorf (TG4.DU).

The revenue cannot currently be calculated for Oxurion.

The expected profit of Oxurion is -92,134.16 EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Oxurion is currently -0.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oxurion stock.

The P/S cannot be calculated for Oxurion currently.

The Eulerpool Quality Score for Oxurion is 2/10.

The ISIN of Oxurion is BE0974487192. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Oxurion is A0J30B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Oxurion is OXUR.BR. The ticker symbol is used to trade Oxurion shares on the stock exchange.

Fair ValueTerminal
0.00 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
38.96 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website oxurion.com
Country
Belgium
Currency
EUR
Initial public offering
Jul 7, 2006
ISIN
BE0974487192
Cusip
B6S90T102
Sedol
B18S7K1
Market capitalization
3,830.64 EURMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.01
P/Ee 2026
-0.04
P/S
P/Se
—
EV/EBIT
28.47
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
44.24 %
Last updated Oct 9, 2026, 9:44 PM

Oxurion Ticker

BRUSSELS · OXUR.BRDÜSSELDORF · TG4.DUEURONEXT · OXUR.BRFRANKFURT · TG4.FLONDON · 0G99.LLONDON STOCK EXCHANGE · 0G99.LSIX · THR.SW

All fundamentals and in-depth analysis of Oxurion

Our stock analysis for Oxurion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxurion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.